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Objectives: The purpose of this study was to describe the susceptibility of environmental strains of Le-
gionella spp. to 10 antimicrobials commonly used for legionellosis therapy. A study of environmental
strains could be useful to timely predict the onset of antibiotic resistance in the environment before it is
evidenced in clinical specimens.
Methods: The minimum inhibitory concentrations (MICs) of 100 environmental Legionella pneumophila
(Lpn) strains belonging to serogroups (sgs) 1, 6, 8, and 10 were tested using the E-test methodology on
buffered charcoal yeast extract agar supplemented with α-ketoglutarate. The most frequent sgs were
selected from those obtained during microbiological surveillance conducted in 2014 in a hospital in
Southern Italy. The MICs were read after 2 days of incubation at 35 °C in a humidiﬁed atmosphere
without CO2.
Results: All isolates were inhibited by low concentrations of ﬂuoroquinolones and macrolides. Rifampicin
was the most active drug against the isolates in vitro. All Lpn isolates were inhibited by the following
drugs (in decreasing order of their MICs): doxycycline4tigecycline4cefotaxime. The MICs of azi-
thromycin, ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin, and tigecycline were signiﬁcantly lower for Lpn non-
sg 1 than Lpn sg 1 isolates.
Conclusions: Susceptibility testing of Legionella strains to appropriate antibiotics should be performed
often to evaluate the possible emergence of resistance, to improve the outcomes of patients, and to
reduce the direct costs associated with hospitalization.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Legionella pneumophila (Lpn) is a ubiquitous, intracellular mi-
croorganism that causes nosocomial and community pneumonia.
Lpn infections are acquired by the inhalation of aerosols produced
from natural and artiﬁcial aquatic environments, and they have
serious consequences, especially in immunocompromised patients
(Neil and Berkelman 2008; Napoli et al., 2009; Lin et al., 2011).
Although a total of 59 different species and more than 70 ser-
ogroups (sgs) have been identiﬁed (Euzéby, 2015), Lpn sg 1 isInc. This is an open access article u
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.T. Montagna).considered to be responsible for up to 80–90% of human infec-
tions, followed by Lpn sgs 4 and 6 (Fontana et al., 2014).
Environmental and anthropogenic factors play a key role in the
spread of Legionella spp., as ecological factors, geographical area,
and the efﬁcacy of disinfection methods inﬂuence their multi-
plication and survival. In addition, it has been shown that the
presence of antibiotics in the environment may promote the
evolution of microbial resistance mechanisms (D’Costa et al.,
2006). This is particularly important for Legionella spp. that colo-
nize environmental water systems, where they may be exposed to
antibiotics from medical or veterinary practices, or even to those
secreted by other microorganisms (Almahmoud et al., 2009).
Although several studies have examined the environmental
reservoirs of Legionella spp. (Montagna et al., 2006; Napoli et al.,
2010; Pasquarella et al., 2012; Montagna et al., 2014), their anti-
microbial susceptibility has received less attention (Gómez-Lus
et al., 2001; Erdogan et al., 2010; Al-Matawah et al., 2012; San-
dalakis et al., 2014). The study of antibiotic susceptibility in clinical
strains is complicated by different factors: Legionnaires' disease is
usually a non-productive pneumonia, and it is difﬁcult to obtainnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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antibiotic therapy. In addition, the in vitro activity of commonly
employed antibiotics is difﬁcult to interpret because the minimum
inhibitory concentration (MIC) distributions of wild-type strains,
as well as epidemiological cut-off values, have not been described
(Bruin et al., 2012).
Because of the ability of Legionella spp. to survive and multiply
in human macrophages, they are susceptible to antimicrobial
agents that are active intracellularly (Bruin et al., 2012). Macro-
lides, ﬂuoroquinolones, and rifampicin are the antimicrobials most
commonly used in the treatment of legionellosis (Sabrià et al.,
2005), although some studies have reported treatment failure in
patients receiving therapy with these antibiotics (Blázquez Garrido
et al., 2005; Erdogan et al., 2010).
The aim of this study was to describe the antibiotic suscept-
ibility of environmental strains of Legionella spp. that were se-
lected from those obtained during microbiological surveillance
conducted in 2014 in a hospital in Southern Italy. A study of en-
vironmental strains could be useful, not only for epidemiological
purposes (such as verifying the distribution of susceptibility/re-
sistance of strains in a geographical area), but also for timely
prediction of the onset of antibiotic resistance in the environment
before it is evidenced in clinical specimens.2. Material and methods
2.1. Setting
The study was conducted in a university hospital in the Apulia
region (Southern Italy), which is composed up of 32 buildings,
including 22 ward buildings, with a total bed capacity of about
1400. Since 2000, the hospital water system has been under en-
vironmental surveillance for the detection of Legionella spp. For
the last 7 years, according to the procedures described in the Ita-
lian Guidelines (LG, 2000), a standardized protocol of surveillance
has been adopted in all 22 ward buildings. At least six sampling
points for each ward building were monitored twice per year.
2.2. Legionella strains selection
During the last 7 years of environmental surveillance, the most
commonly isolated Legionella strains were Lpn sg 1 (29.41%), Lpn
sg 10 (29.23%), Lpn sg 6 (20.54%), Lpn sg 8 (3.18%), Lpn sg 3 (0.75%),
Lpn sg 7 (0.47%), Lpn sg 12 (0.37%), L. micdadei (0.28%), Lpn sg 14
(0.09%), L. gormanii (0.09%), L. bozemanii (0.09%), and mixed cul-
tures (15.5%). All the isolates were ﬁrst serologically identiﬁed by
the latex agglutination test using a polyvalent commercial kit
(Oxoid S.p.A., Milan, Italy), then by a panel of monovalent antisera
(Biogenetics S.R.L., Denka Seiken, Ponte San Nicolò, Italy). No no-
socomial cases were reported in the same period from the hospital
and, therefore, no clinical strains were isolated.
During the last year of surveillance (January–December 2014),
Lpn sgs 1 (31.27%), 10 (29.09%), 6 (24.36%), and 8 (8.73%) were the
most frequently isolated strains according to reports of human
legionellosis cases (Fendukly et al., 2007; Kawanami et al., 2011;
Zhang et al., 2014). For this reason, a sample of 25 Lpn strains from
each of the four most frequently isolated sgs was selected, which
yielded a total of 100 Lpn strains.
Lpn sg 1 American Type Culture Collection (ATCC) 33152 was
used as the reference strain. To determine the inﬂuence of char-
coal (present in buffered charcoal yeast extract agar supplemented
with α-ketoglutarate, BCYE-α) on the activity of the anti-
microbials, Staphylococcus aureus ATCC 29213 was also selected for
susceptibility testing. The selected strains were frozen at 80 °C
prior to analysis.2.3. Susceptibility testing
Susceptibility testing was performed using E-tests on BCYE-α
(Lioﬁlchem S.R.L., Teramo, Italy). Ten antimicrobial drugs were
tested: azithromycin (AZI), cefotaxime (CEF), clarithromycin (CLA),
doxycycline (DOX), erythromycin (ERY), rifampicin (RIF), and ti-
gecycline (TIG) (ranging from 0.016 to 256 mg/L each), as well as
ciproﬂoxacin (CIP), levoﬂoxacin (LEV), and moxiﬂoxacin (MOX)
(ranging from 0.002 to 32 mg/L each). The MIC of each antibiotic
was taken as the lowest concentration of antibiotic at which the
zone of inhibition intersected the E-test strip.
Legionella strains were sub-cultured on BCYE-α plates and in-
cubated for 48 h at 37 °C in a humidiﬁed atmosphere. Colonies
were suspended in sterile water, and the turbidity was adjusted to
an optical density equivalent to 0.5 McFarland units. Suspensions-
approximately 107 colony-forming units (cfu)/mL-were swabbed
onto BCYE-α plates, and the surfaces of the plates were allowed to
completely dry (15 min at room temperature). Then, antimicrobial
strips (AB-BIODISK, BioMérieux, Marcy l'Etoile, France) were ap-
plied to each inoculated plate. The plates were incubated at 35 °C
(without CO2) for 48 h before reading the MIC value; if no growth
was detected, the plates were incubated for an additional 24 h.
For S. aureus ATCC 29213, the E-test was performed on Mueller-
Hinton agar (MH, Biolife, Milan, Italy) and on BCYE-α, and the MIC
was read after 24 h of incubation at 35 °C.
2.4. Analysis of results
MIC data are presented as the range, geometric mean, MIC50
(the MIC causing inhibition of 50% of isolates), and MIC90 (the MIC
causing inhibition of 90% of isolates) for each sg. The Mann–
Whitney test was applied to evaluate the likely signiﬁcance of
differences in antimicrobial susceptibility between Lpn sg 1 and
non-sg 1 isolates. Moreover, the differences in antimicrobial sus-
ceptibility patterns between Lpn non-sg 1 isolates were evaluated
using the Kruskal–Wallis test, followed by a Dunn's test for mul-
tiple comparisons. Statistical analyses were conducted with
GraphPad Prism version 5.0 for Windows (San Diego, CA, USA),
and statistical signiﬁcance was deﬁned as po0.05.3. Results
The cumulative percentages of 100 environmental Lpn isolates
inhibited by different concentrations of the 10 antimicrobials
tested, as well as the MIC50 and MIC90 values, are shown in Table 1.
Overall, the MIC50 and MIC90 values for the macrolides (AZI, CLA,
and ERY) ranged from 0.016 to 32. In particular, they were 0.047
and 0.25 mg/L, respectively, (range 0.016–4) for AZI, 0.032 and
0.125 mg/L, respectively, (range 0.016–32) for CLA, and 0.094 and
0.125 mg/L, respectively, (range 0.032–16) for ERY.
The MIC50 and MIC90 values for the ﬂuoroquinolones (CIP, LEV,
and MOX) ranged from 0.023 to 3. Speciﬁcally, they were 0.19 mg/L
(range 0.047–2) for CIP (both values), 0.047 and 0.094 mg/L, re-
spectively, (range 0.023–1) for LEV, and 0.19 and 0.25 mg/L, re-
spectively, (range 0.125–3) for MOX. The MIC50 and MIC90 values
for CEF were 0.38 and 1 mg/L, respectively, (range 0.016–1), and
1 and 1.5 mg/L, respectively, for TIG (range 0.19–4). DOX was the
least active drug, with an MIC50¼1.5 mg/L and an MIC90¼2 mg/L,
with MICs ranging from 0.032 to 8 mg/L. RIF was the most active
drug, with an MIC90 of 0.016 mg/L (range 0.016–4).
The activity of ten antimicrobial agents tested against Lpn sg 1,
6, 8 and 10 is shown in Table 2. When comparing the MIC values of
Lpn sg 1 versus non-sg 1 isolates, no differences were found for
ﬁve antibiotics (CEF, CLA, DOX, ERY, and RIF). In contrast, the MIC
values of AZI, CIP, LEV, MOX, and TIG were signiﬁcantly lower for
Table 1
Cumulative distribution of the MICs of 100 environmental Legionella pneumophila isolates.
Drug Cumulative % of strains inhibited at indicated concentrations (mg/L)
0.016 0.023 0.032 0.047 0.064 0.094 0.125 0.19 0.25 0.38 0.5 0.75 1 1.5 2 3 4 8 16 24 32
Azithromycin 8 19 39 71 82 83 89 91 94 97 99 100
Cefotaxime 2 3 8 20 25 38 54 69 87 100
Ciproﬂoxacin 2 3 6 38 90 95 97 98 100
Clarithromycin 1 5 58 75 78 88 94 97 98 99 100
Doxycycline 1 2 3 6 9 26 58 95 97 98 100
Erythromycin 2 10 34 71 91 97 98 100
Levoﬂoxacin 1 24 59 87 97 98 100
Moxiﬂoxacin 8 65 95 97 98 100
Rifampicin 97 98 99 100
Tigecycline 1 6 15 34 72 92 93 94 100
MIC50 and MIC90 values can be read directly from this table.
Table 3
MICs (mg/L) of the two reference strains.
Drug L. pneumophila sg ATCC 12821 S. aureus ATCC 29213
BCYE-α BCYE-α MH
Azithromycin 0.032 2 0.75
Cefotaxime 0.75 0.75 0.75
Ciproﬂoxacin 0.38 0.75 0.38
Clarithromycin 0.032 0.38 0.19
Doxycycline 1.5 0.125 0.125
Erythromycin 0.094 0.25 0.25
Levoﬂoxacin 0.094 0.38 0.19
Moxiﬂoxacin 0.19 0.25 0.012
Rifampicin 0.006 0.012 0.004
Tigecycline 1.5 0.38 0.032
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An analysis of the MICs of each antibiotic against serogroups,
other than Lpn sg 1, revealed some differences. For example, the
MIC value of CEF for Lpn sg 10 was the lowest; for TIG, there was
no signiﬁcant difference between the MIC values of the Lpn sg
6 and sg 8 isolates, while Lpn sg 10 isolates were the most
susceptible.
Regarding the control strains (Table 3), Lpn sg 1 ATCC 33152
(one repetition) generally showed lower sensitivities, with the
exception of CIP (MIC¼0.38 mg/L) and LEV (MIC¼0.094 mg/L),
which were similar to the sensitivities of the environmental iso-
lates. Comparing the results obtained from S. aureus ATCC 29213
(one repetition) on two different media, BCYE-α and MH, AZI ex-
hibited the highest MIC (2 mg/L), and the MICs of AZI, TIG, and
MOX were the most inﬂuenced by charcoal.MH, Mueller-Hinton agar; BCYE-α, buffered charcoal yeast agar.4. Discussion
Environmental surveillance of Lpn contamination, apart from
having a great role in risk assessment, can be of great help in
identifying changes in antibiotic susceptibility. With regard to this
issue, to date, there have been few observational reports, espe-
cially regarding clinical isolates (Blázquez Garrido et al., 2005;Table 2
MIC values (mg/L) for L. pneumophila sg 1, 6, 8, and 10.
Drug L. pneumophila sg 1 L. pneumophila sg 6
MIC50 MIC90 GM MIC50 MIC90 G
Azithromycin 0.19 0.5 0.101 0.047 0.064 0
Cefotaxime 0.5 1 0.369 0.75 1 0
Ciproﬂoxacin 0.19 0.38 0.187 0.125 0.19 0
Clarithromycin 0.032 0.125 0.046 0.047 0.125 0
Doxycycline 1.5 3 1.542 1.5 2 1
Erythromycin 0.094 00:19 0.098 0.094 0.125 0
Levoﬂoxacin 0.064 0.094 0.063 0.047 0.064 0
Moxiﬂoxacin 0.25 0.25 0.227 0.19 0.25 0
Rifampicin 0.016 0.016 0.016 0.016 0.016 0
Tigecycline 1.5 4 1.527 1 1.5 0
GM¼geometric meanSabrià et al., 2005; Gómez-Lus et al., 2001). To our knowledge, ours
is the ﬁrst survey of the antimicrobial susceptibility of Legionella
spp. isolated from hospital water systems in Italy.
Our study conﬁrms that our Lpn isolates are inhibited by low
concentrations of macrolides and ﬂuoroquinolones (Al-Matawah
et al., 2012). Among the macrolides, CLA is the most active drug for
Lpn sg 1, and its activities toward Lpn sg 1 and non-sg 1 isolatesL. pneumophila sg 8 L. pneumophila sg 10
M MIC50 MIC90 GM MIC50 MIC90 GM
.052 0.032 0.064 0.035 0.032 0.19 0.054
.643 0.38 0.75 0.32 0.19 0.38 0.173
.151 0.19 0.19 0.167 0.19 0.25 0.184
.060 0.032 0.064 0.037 0.047 0.125 0.067
.267 2 2 1.706 1.5 2 1.352
.102 0.094 0.125 0.085 0.094 0.125 0.101
.051 0.047 0.064 0.047 0.047 0.094 0.058
.214 0.19 0.25 0.202 0.19 0.38 0.225
.019 0.016 0.016 0.016 0.016 0.016 0.020
.930 1 1.5 1.007 0.75 1.5 0.699
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et al., 2012).
The MIC90 value for AZI is consistent with the results of other
studies that investigated the susceptibility of clinical isolates
(Dunbar and Farrell, 2007). Overall, the MIC50 and MIC90 values of
AZI were signiﬁcantly lower for Lpn non-sg 1 than sg 1 isolates;
this highlights that signiﬁcant differences in antibiotic suscept-
ibility can be reported among different sgs of the same specie with
possible implication in the choice of the best therapy.
In contrast, Gómez-Lus et al. (2001) reported that the MIC va-
lues of macrolides are comparable for Lpn sg 1, 6, 8, and 10 isolates.
These results differ from those of our study probably because of
the different geographical origin, different methodology used, and
the different origins of the strains (nosocomial or community vs.
clinical or environmental).
In our study, the activities of the ﬂuoroquinolones toward Lpn
were similar to those of the macrolides based on MIC90 values
(0.25 mg/L). In contrast, other studies reported that quinolones have
greater activities toward Lpn compared with macrolides, with a de-
creased time to defervescence, reduced length of stay, and reduced
time to clinical resolution; however, these differences probably result
from differences in the susceptibility testing methods used (Blázquez
Garrido et al., 2005; Pedro-Botet and Yu, 2006; Sabrià et al., 2005;
Dunbar and Farrell, 2007). In fact, various methods have been used to
determine MIC values: the E-test, broth and agar dilution, disk dif-
fusion methods, in vivo animal studies, and in vitro cell culture
models. None of these methods is considered to be a gold standard
(Bruin et al., 2012), and some studies showed that using a different
methodology resulted in some variability in the range of MIC values
(García et al., 2000). Overall our results are comparable with studies
that used the same E-test method on BCYE-α agar (García et al.,
2000; Bruin et al., 2012).
Thus far, in the treatment of lower respiratory tract infections,
ﬂuoroquinolones have become the most widely used agents be-
cause of their broad-spectrum coverage, their ease of administra-
tion, and their comparatively fewer adverse effects (Erdogan et al.,
2010). As reported by others (Dunbar and Farrell 2007; Stout et al.,
2005), in our study, LEV was the most active quinolone against Lpn
sg 1 and non-sg 1 isolates despite the use of different susceptibility
tests and differences in the origins of the strains (clinical vs.
environmental).
In accordance with other studies (Marques and Piedade, 1997;
Dubois and St-Pierre, 1999; Erdogan et al., 2010; Bruin et al., 2012;
Al-Matawah et al., 2012; Sandalakis et al., 2014), in our study, RIF
was the most active drug in vitro against both Lpn sg 1 and non-sg
1 isolates. With regard to this antimicrobial, it should be noted
that resistance develops rapidly upon RIF exposure, precluding its
use as a monotherapy for Lpn (Nielsen et al., 2000), although
Varner et al. (2011) reported that RIF combination therapy should
be considered for patients with severe disease or signiﬁcant co-
morbidity conditions (e.g., uncontrolled diabetes, smoking, or
obstructive lung disease), including those who were refractory to
conventional monotherapy regimens.
According to other studies (Marques and Piedade, 1997; Al-
Matawah et al., 2012; Bruin et al., 2012; Sandalakis et al., 2014), all
Lpn isolates were inhibited by (in decreasing order of their MICs)
DOX4TIG4CEF, although they all exhibited higher MICs than the
other antimicrobial drugs tested.
Although only a few studies (Gómez-Lus et al., 2001; Al-Matawah
et al., 2012) have compared the sensitivities of Lpn non-sg 1 isolates
to each antibiotic, our study yielded the same results. Differences in
susceptibility between sg 1 and non-sg 1 isolates were detected only
for CEF and TIG, whereas DOX inhibited all sgs equally.
In our hospital, CLA and LEV are the most used macrolides and
ﬂuoroquinolones, respectively, in treatment of pneumonia. RIF is
not used because of its adverse effects, especially when incombination with other drugs (Varner et al., 2011).
Regarding to differences observed in susceptibility of S. aureus
ATCC 29213 to TIG, MOX and AZI according to the different media
used, several studies have indicated that charcoal or other com-
ponents of BCYE-α agar can inhibit various antibiotics, including
tetracyclines, ﬂuoroquinolones, and macrolides (Marques and
Piedade, 1997; García et al., 2000; Gómez-Lus et al., 2001; Erdogan
et al., 2010; Bruin et al., 2012; Sandalakis et al., 2014). In particular
in our study, S.aureus resulted resistant to AZI in BCYE-α agar and
susceptible in MH according to EUCAST clinical breakpoint
table (EUCAST, 2015). As reported by some authors (Marques and
Piedade, 1997; Gómez-Lus et al., 2001; Erdogan et al., 2010), the
use of BYE-α (without charcoal) instead of BCYE-α may be a good
option to choose for the in vitro testing of susceptibility of Legio-
nella spp. to antimicrobials.
Although performing the E-test on BCYE-α agar may yield
elevated MICs, we used the E-test on BCYE-α because it represents
a simple, readily available, and accurate method for routine sus-
ceptibility testing of Legionella spp. (Bruin et al., 2012). The E-test
has proven itself over the years, and it can be easily used in many
laboratories, precluding the need to send the strains to reference
laboratories for susceptibility testing. Further studies should be
speciﬁcally addressed to better investigate the antibiotic resistance
of Legionella using BCYE-α versus BYE-α.
Some limitations of this study are that the high costs of these
susceptibility tests make it prohibitively expensive to examine the
antibiotic susceptibility of all strains isolated during routine en-
vironmental surveillance; however, a periodical assessment (e.g.,
every 3–5 years) should be conducted, especially in hospital en-
vironments where resistance is likely (Jonas et al., 2003). Moreover,
caution should be taken when interpreting the results. It should be
considered that in vitro testing of antimicrobial agents sometimes
poorly correlates with clinical efﬁcacy, as the intracellular location of
the microorganisms may protect them from an otherwise effective
antimicrobial therapy (Marques and Piedade, 1997).
Finally, we did not investigate all sgs found in our hospital,
some of which are reported as being pathogenic for humans (e.g.,
Lpn sgs 3 and 7).5. Conclusions
Susceptibility testing of strains to appropriate antibiotics
should be performed often to evaluate the possible emergence of
resistance, to improve the outcomes of patients, and to reduce the
direct costs associated with hospitalization. In some cases, un-
fortunately, the difﬁculties in isolating clinical strains preclude
these kinds of studies. Therefore, for pathogens with environ-
mental reservoirs, such as Legionella spp., an antibiotic suscept-
ibility study of environmental strains, which are more easily de-
tected, can be used to provide an early warning of the onset of
antibiotic resistance, although results should be interpreted with
due caution.Conﬂict of interest
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